Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02679079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Tourette Syndrome

Interventions

DRUG: NBI-98854
DRUG: Placebo

Sponsor

Neurocrine Biosciences